Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs. In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia sits down with Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter, Ph.D., to discuss the significance of Revolution Medicines’ recent pancreatic cancer approval, Verastem’s work in the RAS-targeting space and how the company is trying to improve on existing approaches. To learn more about the topics in this episode: FDA greenlights Revolution Medicines' pancreatic cancer gamechanger As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground ASCO: Revolution Medicines confident in RAS leadership as rivals square up AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises Fierce 50 of 2026: Breakthrough honoree Verastem Oncology Fierce 50 of 2026: Breakthrough honoree Revolution Medicines See omnystudio.com/listener for privacy information.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Top Line
Inside the growing world of biopharma prediction markets
Clinical trials reach a new automation inflection point (Sponsored)
The people who stayed with the problem
Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)
Get summaries like this every morning.
Free AI-powered recaps of The Top Line and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.